Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: ProQR is a biotechnology company focused on developing RNA-based therapeutics using its proprietary Axiomer RNA editing platform. In 2022, the company refocused its strategy exclusively on this platform, divesting its late-stage ophthalmology assets (sepofarsen and ultevursen) to Laboratoires Théa in December 2023. The company has no approved products and has not generated product revenue to date.
Key Financial Metrics
| Metric | 2024 (€) | 2023 (€) |
|---|---|---|
| Revenue | 18,905,000 | 6,514,000 |
| Net Loss | (27,763,000) | (27,735,000) |
| Research & Development Costs | (36,356,000) | (25,148,000) |
| General & Administrative Costs | (13,661,000) | (16,236,000) |
| Cash and Cash Equivalents (Dec 31, 2024) | 149,408,000 | 118,925,000 |
| Accumulated Deficit | (427,158,000) | (400,850,000) |
| Outstanding Ordinary Shares | 105,212,527 | 84,248,384 |
Note: The filing does not provide specific gross or operating margin percentages as the company is pre-revenue from product sales and operates at a loss.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately 190% (€12.4 million) compared to 2023. This was driven primarily by milestone payments and revenue recognition from the collaboration agreement with Eli Lilly and Company.
- R&D Expenses: Increased by €11.2 million (45%) due to higher outsourced R&D activities, increased employee benefits, and investments in the Axiomer platform and internal pipeline targets.
- Financing Activities: In October 2024, the company completed an underwritten public offering and a concurrent private placement with Eli Lilly, raising net proceeds of approximately €71.6 million. This significantly bolstered cash reserves.
- Other Income: Decreased from €3.0 million in 2023 to €0.6 million in 2024. The 2023 figure included a net gain of €2.9 million from the divestment of ophthalmic assets to Théa, which did not recur in 2024.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes that existing cash and cash equivalents of €149.4 million are sufficient to fund anticipated operations into mid-2027. The company expects to continue incurring significant losses as it advances its pipeline.
Pipeline Progress:
- AX-0810 (Cholestatic Diseases): First-in-human clinical trial scheduled for 2025; topline data expected in Q4 2025.
- AX-2402 (Rett Syndrome): Clinical candidate selection expected in 2025; clinical trial initiation expected in 2026.
- AX-1412 (Cardiovascular Disease) & AX-2911 (MASH): Development activities planned for 2025.
Key Risks and Contingencies:
- Capital Needs: The company requires additional capital to fund operations and may need to raise funds sooner than planned if development costs increase or timelines extend.
- Regulatory Uncertainty: Success depends on obtaining regulatory approval for novel RNA editing technologies, which are unproven in humans.
- Collaboration Dependence: Future revenue is heavily dependent on the success of partners (e.g., Eli Lilly, Théa) in developing and commercializing products.
- Intellectual Property: The company faces patent oppositions in Australia and Europe regarding its Axiomer platform.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2027" liquidity estimate against current burn rates and potential delays in clinical trials.
- Lilly Collaboration Milestones: Confirm the specific development milestones achieved in 2024 that triggered the €5.1 million in revenue and assess the probability of future milestones.
- AX-0810 Trial Status: Monitor the timeline for the 2025 first-in-human trial initiation and any regulatory feedback received.
- Patent Oppositions: Review the status of ongoing patent oppositions in Europe and Australia regarding the Axiomer platform.
- Dilution Risk: Assess the impact of outstanding options (approx. 11.7 million) and warrants (approx. 2.8 million) on future share count.